Yarbrough Capital’s Axsome Therapeutics AXSM Stock Holding History

Yarbrough Capital’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,054	Closed	-$923K	–	95
2025 Q4	$923K	Hold	5,054	–	–	0.03%	91
2025 Q3	$614K	Hold	5,054	–	–	0.02%	112
2025 Q2	$528K	Hold	5,054	–	–	0.02%	125
2025 Q1	$589K	Hold	5,054	–	–	0.03%	125
2024 Q4	$428K	Hold	5,054	–	–	0.02%	137
2024 Q3	$454K	Hold	5,054	–	–	0.02%	142
2024 Q2	$407K	Hold	5,054	–	–	0.02%	145
2024 Q1	$403K	Buy	+5,054	New	+$424K	0.02%	152

Other funds holding AXSM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Yarbrough Capital's AXSM Position: Q1 2026 in Review

Yarbrough Capital sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 5,054 shares — an estimated $923K sold.

Yarbrough Capital first reported a position in AXSM in Q1 2024 and held it in 8 quarters. The position peaked at $923K in Q4 2025. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

Yarbrough Capital reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
Yarbrough Capital sold 5,054 Axsome Therapeutics shares in Q1 2026, an estimated $923K.
Yarbrough Capital first reported a position in Axsome Therapeutics in Q1 2024 and held it in 8 quarters.
Yarbrough Capital's Axsome Therapeutics position peaked at $923K in Q4 2025.
409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on Yarbrough Capital's 13F filing for Q1 2026, filed 14 Apr 2026.